ABL and affiliates plan to start the production and commercialization of new UltraGene products based on PCR tests previously supplied by Fast Track Diagnostics
ABL Diagnostics SA (EPA:ABLD)
LUXEMBOURG VILLE, LUXEMBOURG, February 3, 2025 /EINPresswire.com/ — Advanced Biological Laboratories (ABL), a diagnostics company, headquartered in Luxembourg, announces that the licensing and transfer agreement of know-how and IP rights from Fast Track Diagnostics Luxembourg (FTD) has been inked with Siemens Healthineers.
FTD was engaged in the development, manufacturing and selling of in-vitro diagnostic and research use only molecular testing products. Siemens Healthineers, as the owner of FTD, licensed and transferred the know-how and IP rights to ABL and its affiliates (ABL Group) related to the design and manufacturing of certain former FTD products.
Based on this Know-How License and Transfer Agreement (Agreement) the ABL group intends to manufacture and commercialize its own testing products equivalent to the former FTD products. Financial details of the deal were not disclosed.